Anna Gilbert

Anna Gilbert has over 20 years of experience in Quality Assurance in Biotechnology, with the last 8 years focused in cell therapy. Anna is currently the Director of Quality at Nohla Therapeutics, Inc. Prior to Nohla, Anna has prior experience at several biotech companies. Most recently she started in January 2014 at Juno Therapeutics as one of the earliest employees and the first in Quality Assurance. She established the first quality systems for Juno and managed the GMP quality compliance program. At Dendreon, Anna managed all aspects of GMP and GTP quality compliance, including internal and external auditing as well as compliance oversight of apheresis sites. She joined Dendreon in 2009 and participated in the successful pre-approval inspection of the first US commercial cell therapy, Provenge. During her tenure at Amgen she supported quality operations for manufacturing, quality control, validation and new product introduction for clinical phase monoclonal antibodies. Anna had the good fortune to arrive at Immunex in 1998, just prior to the launch of Enbrel, at the time the most successful biotech product launch. Anna began her career at Chiron, supporting the lot disposition of diagnostic kits for blood screening. Anna is an ASQ Certified Quality Auditor and a member of the Parenteral Drug Association (PDA). She delivers an annual lecture on the topic of GMP auditing at University of Washington’s Master of Science in Biomedical Regulatory Affairs program.